Dréno, Brigitte

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

McArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 977

European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version

Nast, A., Dréno, B., Bettoli, V., Bukvic Mokos, Z., Degitz, K., Dressler, C., Finlay, A. Y., Haedersdal, M., Lambert, J., Layton, A., et al. (2016) · Journal of the European Academy of Dermatology and Venereology

Acne and Rosacea Treatments and EffectsClinical practice guidelines implementation

Cited by 393

Microbiome in healthy skin, update for dermatologists

Dréno, B., Araviiskaia, E., Berardesca, E., Gontijo, G., Sanchez Viera, M., Xiang, L. F., Martin, R., & Bieber, T. (2016) · Journal of the European Academy of Dermatology and Venereology

Dermatology and Skin DiseasesGut microbiota and health

Cited by 292

Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel

Passeron, T., Lim, H. W., Goh, C. ‐., Kang, H. Y., Ly, F., Morita, A., Ocampo Candiani, J., Puig, S., Schalka, S., Wei, L., et al. (2021) · Journal of the European Academy of Dermatology and Venereology

Skin Protection and Agingmelanin and skin pigmentation

Cited by 221

Large‐scale worldwide observational study of adherence with acne therapy

Dréno, B., Thiboutot, D., Gollnick, H., Finlay, A. Y., Layton, A., Leyden, J. J., Leutenegger, E., Perez, M., & on behalf of the Global Alliance to Improve Outcomes in Acne (2010) · International Journal of Dermatology

Medication Adherence and ComplianceAcne and Rosacea Treatments and Effects

Cited by 195

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

Gogas, H., Dréno, B., Larkin, J., Demidov, L., Stroyakovskiy, D., Eroglu, Z., Francesco Ferrucci, P., Pigozzo, J., Rutkowski, P., Mackiewicz, J., et al. (2021) · Annals of Oncology

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 102

Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6-month randomized, vehicle-controlled trial using intra-individual comparison

Dréno, B., Bissonnette, R., Gagné-Henley, A., Barankin, B., Lynde, C., Kerrouche, N., & Tan, J. (2018) · American Journal of Clinical Dermatology

Acne and Rosacea Treatments and EffectsDermatologic Treatments and Research

Cited by 69

Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study

Xia, E., Han, J., Faletsky, A., Baldwin, H., Beleznay, K., Bettoli, V., Dréno, B., Goh, C. L., Stein Gold, L., Gollnick, H., et al. (2022) · JAMA Dermatology

Acne and Rosacea Treatments and EffectsDermatology and Skin Diseases

Cited by 40

26274 A dermocosmetic used in combination with the fixed combination adapalene 0.1% and benzoylperoxide 5% helps to protect the skin barrier in mild to moderate acne

Dréno, B., Khammari, A., & Duhamelle, K. (2021) · Journal of the American Academy of Dermatology

Acne and Rosacea Treatments and EffectsDermatology and Skin Diseases

Cited by 1